Agents Targeting Prostate Cancer Bone Metastasis

被引：7

作者：

Mohammad, Khalid S. ^{[1
]}

Fournier, Pierrick G. ^{[1
]}

Guise, Theresa A. ^{[1
]}

Chirgwin, John M. ^{[1
]}

机构：

[1] Indiana Univ, Dept Med, Div Endocrinol, Sch Med, Indianapolis, IN 46202 USA

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 10期

关键词：

Prostate cancer; bone; metastasis; osteolytic; osteoblastic; bisphosphonate; RANK ligand; endothelin; TGF-beta; HUMAN BREAST-CANCER; GROWTH-FACTOR-BETA; NITROGEN-CONTAINING BISPHOSPHONATES; CALCIUM-SENSING RECEPTOR; CELL-LINE PC-3; ZOLEDRONIC ACID; IN-VIVO; SKELETAL METASTASES; TUMOR-GROWTH; FLUORESCENT PROTEINS;

D O I：

10.2174/187152009789735008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

引用

页码：1079 / 1088

页数：10

共 103 条

[1]

Ahmad Imran, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000689

[2]

Barnes GL, 2003, CANCER RES, V63, P2631

[3] Inhibition of transforming growth factor-β signaling in human cancer:: Targeting a tumor suppressor network as a therapeutic strategy [J].

Biswas, Swati ;

Criswell, Tracy L. ;

Wang, Shizhen Emily ;

Arteaga, Carlos L. .

CLINICAL CANCER RESEARCH, 2006, 12 (14) :4142-4146

[4] Wnt signaling and osteoblastogenesis [J].

Bodine, Peter V. N. ;

Komm, Barry S. .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2006, 7 (1-2) :33-39

[5]

Boissier S, 1997, CANCER RES, V57, P3890

[6] Src inhibitors in metastatic bone disease [J].

Boyce, Brendan F. ;

Xing, Lianping ;

Yao, Zhengiang ;

Yamashita, Teruhito ;

Shakespeare, William C. ;

Wang, Yihan ;

Metcalf, Chester A., III ;

Sundaramoorthi, Raji ;

Dalgarno, David C. ;

Luliucci, John D. ;

Sawyer, Tomi K. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6291S-6295S

[7] Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment [J].

Brubaker, KD ;

Brown, LG ;

Vessella, RL ;

Corey, E .

BMC CANCER, 2006, 6 (1)

[8] High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities? [J].

Bruland, Oyvind S. ;

Nilsson, Sten ;

Fisher, Darrell R. ;

Larsen, Roy H. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6250S-6257S

[9] Inhibition of bone resorption and growth of breast cancer in the bone microenvironment [J].

Buijs, Jeroen T. ;

Que, Ivo ;

Lowik, Clemens W. G. M. ;

Papapoulos, Socrates E. ;

van der Pluijm, Gabri .

BONE, 2009, 44 (02) :380-386

[10] The bone microenvironment in metastasis; what is special about bone? [J].

Bussard, Karen M. ;

Gay, Carol V. ;

Mastro, Andrea M. .

CANCER AND METASTASIS REVIEWS, 2008, 27 (01) :41-55

← 1 2 3 4 5 6 7 8 9 10 →